On Feb. 11, 2021, the the Military Health System (MHS) announced partcipation in the AstraZeneca phase III clinical trial with its intramuscular monoclonal antibody product, called AZD7442. The phase III clinical trial included five Department of Defense (DOD) sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.